Alg-000184, a new hepatitis B drug under development, has recently applied for clinical application for capsid procedure

According to the recent announcement of aligos therapeutics, its candidate drug alg-000184, which is based on the capsid assembly regulator, has recently submitted an application for clinical trial on the treatment of chronic hepatitis B. At present, aligos therapeutics Co., Ltd. has developed a variety of new hepatitis B drugs with different targets, which are in clinical research. The company is committed to the development of targeted antiviral therapy for viral infection and drug development of nonalcoholic steatohepatitis. < / P > < p > as shown in the above figure, the latest announcement by aligos therapeutics has submitted to the New Zealand drug and medical device safety agency an application for human clinical trial of the candidate drug alg-000184, which is expected to be carried out in healthy volunteers and patients with chronic hepatitis B. In terms of drug mechanism, alg-000184 is a small molecule class II capsid assembly regulator, which aims at the regulation and transcription of viral nucleocapsid assembly steps and viral replication template cccDNA. < / P > < p > the following is from the original comments of CEO of aligos, Raymond schinazi of Emory University In the Ph.D. lab, we have focused on and found a new type of capsid assembly regulator compound. In the past two years, we have continuously improved this new type of capsid assembly regulator. Finally, we found that alg-000184 is the most effective class II capsid assembly regulator candidate drug we have found. We are very happy to pay attention to its enhancement effect in order to enter clinical trials more quickly. < / P > < p > according to the introduction of phase I clinical trial of the drug, alg-000184 is oral administration. Study 201 will evaluate the safety, pharmacokinetics and antiviral activity of alg-000184 once a day for 28 days in healthy volunteers and patients with chronic hepatitis B. Dr. Matthew McClure, chief medical officer of the company, commented: our general direction is that after the candidate drugs of nucleic acid polymer in phase I of clinical trial, other candidate drugs, such as alg-000184, will also enter the clinical trials of combined drugs. We believe that this enhanced synergistic mechanism to improve antiviral activity can change the current situation of low functional cure rate. < / P > < p > we pay attention to a new type of capsid assembly regulator, which is one of the four categories of compounds independently developed by aligos company to treat chronic hepatitis B, including small interfering RNA (siRNA) drugs, antisense oligonucleotides and nucleic acid polymers. The preclinical data of alg-000184, a new hepatitis B drug under development, was released by aligos at this month’s European Symposium on liver disease research. In short, alg-000184 can reduce HBV-DNA and hbv-rna in animal models of chronic hepatitis B. < / P > < p > the researchers introduced in this meeting that alg-000184 is the prodrug of alg-001075, showing more ideal pharmacokinetic characteristics than alg-001075. Xiaofan health noted that at present, the company also has alg-010133, which is in phase I clinical trial and has completed the first patient medication. The company name is private clinical stage biotechnology company. Alg-010133 is mainly based on the optimization of oligonucleotide polymer molecules, which can significantly inhibit the level of hepatitis B surface antigen in patients with chronic hepatitis B. < / P > < p > it is worth mentioning that the four compounds of aligos therapeutics have different therapeutic targets for chronic hepatitis B. At present, antisense oligonucleotides, siRNA, capsid assembly regulators and oligonucleic acid polymers are potential targets for the functional cure of chronic hepatitis B. the company has submitted four new drugs under development. In the early stage, the company also said that after these new target drugs enter human clinical trials, they can be combined to achieve a higher therapeutic goal, namely functional cure. Recently, aligos therapeutics Co., Ltd. submitted a clinical trial application for a new class II capsid assembly regulator alg-000184, which was published in aligos therapeutics company. Interested readers can move to the company for more information. The capsid assembly regulator mainly develops candidate drugs based on the assembly steps of hepatitis B virus capsid and the regulation and transcription process of covalently closed circular DNA. After two years of continuous improvement, the company’s researchers found that alg-000184. < / P > < p > according to the latest announcement, the phase I clinical study of alg-000184 will be a multi-part umbrella test to evaluate the safety, pharmacokinetics and antiviral activity of oral administration once a day for 28 days in healthy volunteers and patients with chronic hepatitis B. At present, aligos therapeutics Co., Ltd. has launched four new hepatitis B drugs with different targets into clinical research. In addition to alg-000184, a novel capsid assembly regulator, it also includes antisense oligonucleotides, small interfering RNA and nucleic acid polymers. 08/16/2020